Market Cap$1.12T
P/E57.33x
PEG Ratio1.22
Div yield0.75%
Beta0.42
LLY Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)26.36%
Price vs S&P 500 (4W)9.23%
PEG Ratio1.22
VGM Score61.11
P/E Ratio (Annual)57.33x
Indicated Dividend Yield (Annual)0.75%
LLY Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $6.58 | $8.38 | +27.27%(+$1.80) | |
| Q1 2026 | $6.79 | $8.55 | +25.90%(+$1.76) | |
| Q4 2025 | $6.91 | $7.54 | +9.14%(+$0.63) | |
| Q3 2025 | $5.89 | $7.02 | +19.15%(+$1.13) | |
| Q2 2025 | $5.59 | $6.31 | +12.89%(+$0.72) |
LLY Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.05
4.05
4.05
4.05
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
| BMYBristol-Myers Squibb Co. | B | B | B | 2.5x | 3.1% | 71.7% | — | $59.75 |
About Eli Lilly & Co.
Eli Lilly is a pharmaceutical company with leading therapeutic portfolios in neuroscience, cardiometabolic disease, cancer, and immunology. The company's key franchises include blockbuster diabetes and obesity treatments (Mounjaro, Zepbound, Jardiance, Trulicity), foundational insulin products (Humalog, Humulin), the cancer therapy Verzenio, and immunology treatments (Taltz, Olumiant).